RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone

NCT ID: NCT02047552

Last Updated: 2019-04-03

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-01-31
• Study Completion Date: 2017-12-31

Brief Summary

The purpose of this trial is to determine if the combination of goal directed iron supplementation and hepcidin mitigation can safely eliminate both the serum and bone marrow iron debt of anemic, critically ill trauma patients with functional iron deficiency.

Detailed Description

The inflammatory response associated with traumatic critical illness rapidly induces a functional iron deficiency, characterized by hypoferremia, decreased transferrin saturation (TSAT), hyperferritinemia, and iron-deficient erythropoiesis (IDE). These derangements in iron metabolism are primarily related to upregulation of the iron regulatory protein hepcidin, which inhibits ferroportin-mediated release of iron from both duodenal enterocytes and macrophages. The resultant functional iron deficiency both contributes to intensive care unit (ICU) anemia and increases the packed red blood cell (pRBCs) transfusion requirement.

Treatment strategies for functional iron deficiency in critically ill patients may be divided broadly into (1) iron supplementation and (2) mitigation of the effects of hepcidin. The goals of treatment are to reverse the serum iron debt, eliminate IDE, improve anemia, and ultimately decrease pRBCs transfusions. Given that approximately 90% of critically ill trauma patients with an ICU length of stay (LOS) ≥ 7 days receive at least one pRBCs transfusion, any strategy that has even a modest impact upon the transfusion requirement is likely to improve overall health outcomes substantially.

Issues surrounding iron supplementation of critically ill patients include formulation, dose, route of administration, hepcidin antagonism, and mitigation of the complications of iron overload, particularly infection. Our first RCT of iron supplementation of critically ill surgical patients compared enteral ferrous sulfate 325 mg thrice daily to placebo (NCT00450177). Although a significant reduction in pRBCs transfusion requirement for the iron group was observed, low injury severity, intolerance of enteral medications, and a predominance of traumatic brain injury limited generalizability. In a second multicenter RCT, we compared intravenous iron sucrose 100 mg thrice weekly to placebo among critically ill trauma patients (NCT01180894, NTI-ICU-008-01) [8]. Iron supplementation using this generic dosing scheme did not impact the serum iron concentration, TSAT, IDE, anemia, or pRBCs transfusion requirement. Rather, iron supplementation accumulated as ferritin as evidenced by a significantly increased serum ferritin concentration in the iron as compared to the placebo group at all time points. Iron supplementation did not increase the risk of infection in either trial, despite a relatively high incidence of marked hyperferritinemia (serum ferritin concentration > 1,000 ng/mL) in the iron group.

The results of these trials suggest that iron supplementation alone, and using a generic dosing scheme, is ineffective. The current pilot trial aims to build upon the findings of the prior two RCTs by incorporating both goal-directed iron supplementation and hepcidin antagonism. The hypothesis is that the combination of goal directed iron supplementation and hepcidin mitigation will safely eliminate both the serum and bone marrow iron debt of anemic, critically ill trauma patients with functional iron deficiency.

Conditions

Functional Iron Deficiency; Trauma; Anemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Iron sucrose

Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT \< 25%, (2) Serum iron concentration \< 150 ug/mL, and (3) Serum ferritin concentration \< 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.

Group Type: ACTIVE_COMPARATOR

Iron sucrose

Intervention Type: DRUG

Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT \< 25%, (2) Serum iron concentration \< 150 ug/mL, and (3) Serum ferritin concentration \< 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.

Oxandrolone placebo

Intervention Type: DRUG

similar color and size sugar pill

Oxandrolone

Oxandrolone 10 mg PO q12 hours will be dosed for seven days.

Group Type: ACTIVE_COMPARATOR

Oxandrolone

Intervention Type: DRUG

10 mg PO Q12 hours for seven days

IV iron placebo

Intervention Type: DRUG

100 mL normal saline

Iron sucrose + oxandrolone

Combination goal-directed iron sucrose (as described in the iron sucrose only arm) and oxandrolone (as described in the oxandrolone only arm) for seven days.

Group Type: EXPERIMENTAL

Iron sucrose

Intervention Type: DRUG

Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT \< 25%, (2) Serum iron concentration \< 150 ug/mL, and (3) Serum ferritin concentration \< 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.

Oxandrolone

Intervention Type: DRUG

10 mg PO Q12 hours for seven days

IV iron placebo and Oxandrolone placebo

100 mL normal saline in place of iron and similar color and size sugar pill for Oxandrolone placebo

Group Type: PLACEBO_COMPARATOR

IV iron placebo

Intervention Type: DRUG

100 mL normal saline

Oxandrolone placebo

Intervention Type: DRUG

similar color and size sugar pill

Interventions

Iron sucrose

Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT \< 25%, (2) Serum iron concentration \< 150 ug/mL, and (3) Serum ferritin concentration \< 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.

Intervention Type: DRUG

Oxandrolone

10 mg PO Q12 hours for seven days

Intervention Type: DRUG

IV iron placebo

100 mL normal saline

Intervention Type: DRUG

Oxandrolone placebo

similar color and size sugar pill

Intervention Type: DRUG

Other Intervention Names

Fe; Steroid; Fe placebo; Steroid placebo

Eligibility Criteria

Inclusion Criteria

1. Informed consent from patient or patient representative.

2. Trauma patient

3. Anemia (hemoglobin < 12 g/dL).

4. Functional iron deficiency:

1. Serum iron concentration < 40 ug/dL

2. TSAT < 25%

3. Serum ferritin concentration > 28 ng/mL

5. < 72 hours from ICU admission.

6. Expected ICU length of stay ≥ 7 days.

Exclusion Criteria

1. Age < 18 years.

2. Active bleeding requiring pRBCs transfusion.

3. Iron overload (serum ferritin concentration ≥ 1,500 ng/mL). The serum ferritin concentration is an acute phase reactant that is increased during critical illness regardless of total body iron. Substantial levels of hyperferritinemia (serum ferritin concentration > 1,000 ng/dL) were observed in both NCT00450177 and NCT01180894 without increased risk of infection and despite both low TSAT and IDE. For these reasons, we believe that relative hyperferritinemia (serum ferritin concentration 500 - 1,500 ng/dL) is neither harmful nor indicative of bone marrow iron availability.

4. Infection, defined using US Centers for Disease Control and Prevention (CDC) guidelines, with the exception of ventilator-associated pneumonia (VAP), which is defined as clinical suspicion for pneumonia along with a lower respiratory tract culture with ≥ 105 colony forming units per mL.

5. Chronic inflammatory conditions (e.g., systemic lupus erythematosis, rheumatoid arthritis, ankylosing spondylitis).

6. Pre-existing hematologic disorders (e.g., thalassemia, sickle cell disease, hemophilia, von Willibrand's disease, or myeloproliferative disease).

7. Pre-existing hepatic dysfunction (cirrhosis, non-alcoholic steatohepatitis, hepatitis)

8. Current or recent (within 30 days) use of immunosuppressive agents.

9. Use of any recombinant human erythropoietin formulation within the previous 30 days.

10. Known or suspected carcinoma of the breast or prostate.

11. Nephrosis, the nephrotic phase of nephritis.

12. Hypercalcemia (serum calcium concentration > 10.5 mg/dL).

13. Pregnancy or lactation.

14. Legal arrest or incarceration.

15. Prohibition of pRBCs transfusion.

16. Stay of ≥ 48 hours duration in the ICU of a transferring hospital.

17. History of intolerance or hypersensitivity to either iron or oxandrolone.

18. Moribund state in which death was imminent.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Denver Health and Hospital Authority

OTHER

Sponsor Role: lead

Responsible Party

Fredric Pieracci

Assistant Professor of Surgery

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Fredric M Pieracci, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

Denver Health Medical Center

Locations

Denver Health Medical Center

Denver, Colorado, United States

Countries

United States

Other Identifiers

14-0167

Identifier Type: -

Identifier Source: org_study_id